Medical Mass Spectrometry Imaging, Department of Pharmaceutical Biosciences, Uppsala University, BMC 591, 75124 Uppsala, Sweden.
Science for Life Laboratory, National Resource for Mass Spectrometry Imaging, Uppsala University, BMC 591, 75124 Uppsala, Sweden.
Anal Chem. 2020 Nov 3;92(21):14676-14684. doi: 10.1021/acs.analchem.0c03203. Epub 2020 Oct 21.
Matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) is an established tool in drug development, which enables visualization of drugs and drug metabolites at spatial localizations in tissue sections from different organs. However, robust and accurate quantitation by MALDI-MSI still remains a challenge. We present a quantitative MALDI-MSI method using two instruments with different types of mass analyzers, i.e., time-of-flight (TOF) and Fourier transform ion cyclotron resonance (FTICR) MS, for mapping levels of the -administered drug citalopram, a selective serotonin reuptake inhibitor, in mouse brain tissue sections. Six different methods for applying calibration standards and an internal standard were evaluated. The optimized method was validated according to authorities' guidelines and requirements, including selectivity, accuracy, precision, recovery, calibration curve, sensitivity, reproducibility, and stability parameters. We showed that applying a dilution series of calibration standards followed by a homogeneously applied, stable, isotopically labeled standard for normalization and a matrix on top of the tissue section yielded similar results to those from the reference method using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The validation results were within specified limits and the brain concentrations for TOF MS (51.1 ± 4.4 pmol/mg) and FTICR MS (56.9 ± 6.0 pmol/mg) did not significantly differ from those of the cross-validated LC-MS/MS method (55.0 ± 4.9 pmol/mg). The effect of citalopram administration on the serotonin neurotransmitter system was studied in the hippocampus, a brain region that is the principal target of the serotonergic afferents along with the limbic system, and it was shown that serotonin was significantly increased (2-fold), but its metabolite 5-hydroxyindoleacetic acid was not. This study makes a substantial step toward establishing MALDI-MSI as a fully quantitative validated method.
基质辅助激光解吸/电离质谱成像(MALDI-MSI)是药物开发中的一种成熟工具,它能够在来自不同器官的组织切片中对药物和药物代谢物进行空间定位可视化。然而,MALDI-MSI 的稳健和准确定量仍然是一个挑战。我们提出了一种使用两种具有不同类型质量分析器的仪器(即飞行时间(TOF)和傅里叶变换离子回旋共振(FTICR)MS)的定量 MALDI-MSI 方法,用于绘制 -administered 药物西酞普兰(一种选择性 5-羟色胺再摄取抑制剂)在小鼠脑组织切片中的水平。评估了六种不同的应用校准标准和内标标准的方法。根据当局的指南和要求,对优化方法进行了验证,包括选择性、准确性、精密度、回收率、校准曲线、灵敏度、重现性和稳定性参数。我们表明,应用校准标准的稀释系列,然后均匀应用稳定的、同位素标记的标准进行归一化,并在组织切片上施加基质,可得到与使用液相色谱-串联质谱(LC-MS/MS)的参考方法相似的结果。验证结果在规定范围内,TOF MS(51.1±4.4 pmol/mg)和 FTICR MS(56.9±6.0 pmol/mg)的脑浓度与经过交叉验证的 LC-MS/MS 方法(55.0±4.9 pmol/mg)没有显著差异。研究了西酞普兰给药对海马体(作为 5-羟色胺传入纤维的主要靶标以及边缘系统的脑区)中 5-羟色胺神经递质系统的影响,结果表明 5-羟色胺显著增加(2 倍),但其代谢物 5-羟吲哚乙酸没有增加。这项研究朝着将 MALDI-MSI 确立为完全定量验证方法迈出了实质性的一步。